Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Sponsored by Abramson Cancer Center at Penn Medicine
About this study
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Where this study is enrolling
- I'm interested
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Who can participate
Inclusion criteria
- ✓Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- ✓Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
- ✓PS 0-1
Exclusion criteria
- ✕Presence of a driver mutation that is susceptible to targeted therapy
- ✕Other active invasive malignancy requiring ongoing therapy
- ✕Grade 2 or higher sensory neuropathy
- ✕Evidence of untreated brain metastases
- ✕History of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.